TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

To join this study, participants generally need to be adults aged 18 or over with advanced or metastatic non-small cell lung cancer (NSCLC). A crucial requirement is that your cancer must have a specific genetic change called an 'EGFR exon 20 insertion mutation'. This will need to be confirmed by a special test.

Key health requirements include being generally well enough to participate, with a good level of physical activity, and having healthy organ function. Your doctors will check if your cancer can be measured to track treatment progress. You must also not have received any previous treatment specifically for your advanced or metastatic lung cancer. However, if you had chemotherapy or radiotherapy for an earlier stage of lung cancer more than six months ago, you might still be eligible.

If you join this study, you will be randomly assigned to one of two groups. One group will receive the new drug, TAK-788, which is taken as tablets by mouth. The other group will receive standard chemotherapy, which will be given directly into your vein (intravenously). You will continue your assigned treatment for as long as it's effective, you can tolerate it, or until the disease significantly worsens. If you are in the chemotherapy group and your disease gets worse, you might have the option to switch to TAK-788.

Participation involves regular visits to the clinic for assessments and to receive your treatment. You will be closely monitored for how well the treatment is working and for any side effects. The total time for the study can be quite long, with follow-ups lasting up to three years after the last person joins the study. These follow-ups will check your survival, any subsequent cancer treatments you receive, how your disease progresses over time, and your general health and quality of life as reported by you.